MindSpire raises £850k in pre-seed funding led by SFC Capital to launch its debut wearable device
The pre-seed round was led by SFC Capital with participation from SyndicateRoom and Innovate UK.
MindSpire develops a medical-grade wearable device and adaptive platform designed to regulate stress and enhance cognitive performance using targeted vagus nerve stimulation and artificial intelligence.
MindSpire has secured £850k in pre-seed funding to finalise and launch its flagship wearable device, SONA. The round was led by SFC Capital, with additional backing from SyndicateRoom and Innovate UK. Based at the London Institute for Healthcare Engineering, the neurotechnology start-up aims to make advanced nervous system care accessible for both high performers and individuals managing chronic conditions.
The capital will support the commercialisation of SONA alongside ongoing research into relieving chronic stress, anxiety, and burnout. MindSpire combines vagus nerve stimulation with real-time biometric sensing to help users optimise mental states and improve resilience.
From the founder
"Our goal is to create a solution that performs just as well for executives managing stress and recovery as it does for individuals rebuilding from chronic conditions. It reflects our commitment to making nervous system care accessible, especially for those who need it most"
Jane Ollis
Founder and CEO at MindSpire
Investor perspective
"We’re delighted to invest in MindSpire and enable them complete the development and launch of SONA™. We look forward to the impact they make in treating chronic stress and anxiety, and to welcome another promising company at the cross section of AI and cutting edge healthtech to the Access EIS portfolio."
Tom Britton
Founding Partner, SyndicateRoom
Use of funds
- 01Continue product development
- 02Fund research and development
.png)
